PIGNATA, S.; CECERE, S. C.; DI MAIO, M. Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  . Cancer Breaking News, [S. l.], v. 4, n. 1, p. 45–47, 2016. DOI: 10.19156/cbn.2016.0009. Disponível em: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/205. Acesso em: 22 jul. 2024.